Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET

Company Participants

Paul Cox - Vice President, Investor Relations & Corporate Communications
Ryan Spencer - Chief Executive Officer
Donn Casale - Chief Commercial Officer
Rob Janssen - Chief Medical Officer
Kelly MacDonald - Chief Financial Officer

Conference Call Participants

Matt Phipps - William Blair
Jon Miller - Evercore
Ernie Rodriguez - TD Cowen
Paul Choi - Goldman Sachs
Roy Buchanan - Citizens

Operator

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's prepared remarks, we will open the call for questions and provide specific participation instructions at that time.

I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin.

Paul Cox

Thank you for participating in today's call. Joining me from Dynavax are Ryan Spencer, Chief Executive Officer; Donn Casale, Chief Commercial Officer; Rob Janssen, Chief Medical Officer; and Kelly MacDonald, our Chief Financial Officer.

Earlier today, Dynavax released financial results for the third quarter ended September 30th, 2024. Copies of the press release and the supplementary slide presentation are available on Dynavax's website.

Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including, but not limited to, potential market sizes, market segmentation, effective marketing efforts, future expected market share, and related growth rates and related ACIP recommendation impact on each financial guidance and trends, including revenue, profitability, cash flow, and sufficiency of current capitalization, timing and results of FDA submissions, clinical trial starts and data readouts and potential future uses of or demand for our CpG-1018 adjuvant.

These statements involve risks and uncertainties and our actual results may differ materially. These risks are summarized in today's press release and detailed in the Risk Factors section of our SEC filings, including today's quarterly report on Form 10-Q. Our forward-looking statements speak as of today and we undertake no obligation to update such statements.

And with that, I will now turn the call over to Ryan.

Ryan Spencer

Thanks Paul and thank you all for joining us this afternoon. It's nice to be here again to share the results of another very successful quarter for Dynavax. Our success continues to be driven by HEPLISAV-B, where the team once again delivered a record quarter with $79 million in net product sales. We are very proud of our accomplishments with HEPLISAV-B from its development to successful commercialization.